Certara (NASDAQ:CERT) Issues FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.420-0.460 for the period, compared to the consensus EPS estimate of 0.450. The company issued revenue guidance of $415.0 million-$425.0 million, compared to the consensus revenue estimate of $420.0 million.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CERT. William Blair reissued a “market perform” rating on shares of Certara in a report on Thursday, February 27th. KeyCorp raised their price target on shares of Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday. Robert W. Baird boosted their price target on shares of Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. Stephens reiterated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Finally, Barclays decreased their target price on Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.17.

Certara Stock Up 4.6 %

Shares of NASDAQ CERT opened at $14.15 on Friday. The stock has a market capitalization of $2.28 billion, a P/E ratio of -70.75, a PEG ratio of 9.29 and a beta of 1.64. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara has a one year low of $8.64 and a one year high of $17.94. The firm’s 50 day simple moving average is $11.62 and its two-hundred day simple moving average is $11.44.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.